Clinical study on Huwang-Mingmu Decoction combined with calcium dobesilate capsules in the treatment of diabetic retinopathy
10.3760/cma.j.cn115398-20190719-00129
- VernacularTitle:护网明目汤联合羟苯磺酸钙胶囊治疗糖尿病视网膜病变临床研究
- Author:
Liping ZHAI
1
;
Xu WANG
Author Information
1. 江苏省泰州市中医院内分泌科 225300
- From:
International Journal of Traditional Chinese Medicine
2020;42(6):530-534
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of Huwang-Mingmu Decoction combined with calcium dobesilate capsules in the treatment of diabetic retinopathy (DR). Methods:A total of 80 DR patients who met the inclusion criteria in Taizhou Hospital of TCM from January 2017 to December 2018 were included, and were divided into two groups according to random number table method, 40 in each group. The control group was treated with calcium dobesilate capsules, and the observation group was treated with Huwang-Mingmu Decoction based on the control group. Both of the two groups were treated for 30 days. The TCM symptoms were scored before and after the treatment, fasting blood glucose (FPG), postprandial 2 h blood glucose (2 hPG), glycosylated hemoglobin (HbAlc) were measured by automatic biochemical analyzer, serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), human intercellular adhesion molecule1 (ICAM-1) were detected by ELISA, the gray value of the visual field and the hemorrhagic plaque area were measured by the projection visual field tester, the macular thickness was measured by the optical coherence tomography, and the ocular hemangioma volume was measured by the X-ray computed tomography, and the clinical effect was evaluated. Results:The total clinical effective rate of the observation group and the control group was 95.00% (38/40) and 80.00% (32/40) respectively of, the difference between the two groups was statistically significant ( χ2=4.114, P=0.043). The scores of the primary symptoms and secondary symptoms in the observation group were significantly lower than those of the control group ( t values were 68.305 and 9.687, respectively, all Ps<0.001). The FPG, 2 hPG and HbAlc in the observation group were significantly lower than those of the control group ( t values were 4.888, 3.007 and 7.183, respectively, all Ps<0.01). The gray value of the visual field (1.41% ± 0.17% vs. 2.55% ± 0.24%, t=24.515), macular thickness (308.85 ± 9.43 μm vs. 358.51 ± 13.24 μm, t=19.322), hemorrhagic plaque area (1.10 ± 0.35 mm 2vs. 2.03 ± 0.44 mm 2, t=10.462) and hemangioma volume (11.02 ± 1.94 μm 3vs. 14.11 ± 2.11 μm 3, t=6.818) in the observation group were significantly lower than those of the control group ( P<0.01). The serum levels of IL-6, TNF-α and ICAM-1 in the observation group were significantly lower than those of the control group ( t values were 32.261, 19.467 and 37.713, respectively, all Ps<0.001). No serious adverse reactions occurred during the treatment period of the two groups. Conclusions:The Huwang-Mingmu Decoction combined with calcium dobesilate capsules is effective in the treatment of DR. It can improve the vision and relieve clinical symptoms of DR patients, decrease the level of blood glucose and inflammatory cytokines, and improve the clinical effect.
